pe0105
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2023 (NCT06026501)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05801237 | Phase 1/Phase 2 (Phase 2) | Sep 21, 2023 | Government of China |
| NCT06026501 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2023 | Government of China, Shanghai YingLi Pharmaceutical Co. Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 1 | 1 | 2023 |
| Shanghai YingLi Pharmaceutical Co. Ltd. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1